Securities code: Shenzhen Yhlo Biotech Co.Ltd(688575) securities abbreviation: Shenzhen Yhlo Biotech Co.Ltd(688575) Announcement No.: 2022025 Shenzhen Yhlo Biotech Co.Ltd(688575)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Shenzhen Yhlo Biotech Co.Ltd(688575) (hereinafter referred to as “the company”) has accumulated more than 30% deviation from the closing price increase within three consecutive trading days (from March 9, 2022 to March 11, 2022). In accordance with the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading.
After the company’s self-examination and sent a letter to ask the controlling shareholder and actual controller, as of March 11, 2022, there were no major matters that should be disclosed but not disclosed.
As of the date of this announcement, the company’s covid-19 virus antigen detection products have not obtained the registration certificate issued by China’s drug administration. Please invest rationally and pay attention to investment risks.
As of March 11, 2022, the closing price of the company was 51.91 yuan / share. According to the data released by China Securities Index Co., Ltd., as of March 10, 2022, the latest rolling P / E ratio of the company is 84.40 times. The average rolling P / E ratio of the pharmaceutical manufacturing industry in which the company is located in the latest month is 28.93 times. The P / E ratio of the company is significantly higher than that of the industry. Please invest rationally and pay attention to investment risks.
1、 Details of abnormal fluctuations in stock trading
Within three consecutive trading days (from March 9, 2022 to March 11, 2022), the cumulative deviation of the closing price increase of the company’s shares has reached more than 30%. According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading.
2、 Relevant information concerned and verified by listed companies
1. Through self inspection, the daily operation of the company is normal in the near future, and there is no significant change. The market environment and industrial policies have not been significantly adjusted, the product R & D, production and sales have been promoted normally, and the internal production and operation order is normal.
2. Confirmed by letter to the controlling shareholder and actual controller of the company, as of March 11, 2022, there are no major events affecting the abnormal fluctuation of stock trading of the listed company; There are no major events that should be disclosed but not disclosed, including but not limited to major asset restructuring, share issuance, debt restructuring, business restructuring, asset divestiture, asset injection and other major events.
3. Except for the matters disclosed in the early stage of the company, the company has not found any other major events that may have a great impact on the share price of the listed company.
4. After verification, the directors, supervisors, senior managers, controlling shareholders and actual controllers of the company did not buy or sell the company’s shares during the abnormal fluctuation of stock trading.
3、 Board statement
The board of directors of the company confirms that the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange on the science and Innovation Board (hereinafter referred to as the Listing Rules of the science and Innovation Board) or the planning and intention related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of the science and innovation board Information that may have a great impact on the trading price of the company’s shares and their derivatives.
4、 Relevant risk tips
(I) concerned about the recent online news report on “China’s covid-19 virus antigen detection application scheme”, as of the date of this announcement, the company’s covid-19 virus antigen detection products have not obtained the registration certificate issued by the China drug administration. Please invest rationally and pay attention to investment risks.
(II) as of March 11, 2022, the closing price of the company was 51.91 yuan / share. According to the data released by China Securities Index Co., Ltd., as of March 10, 2022, the latest rolling P / E ratio of the company is 84.40 times. The average rolling P / E ratio of the pharmaceutical manufacturing industry in which the company is located in the latest month is 28.93 times. The P / E ratio of the company is significantly higher than that of the industry. Please invest rationally and pay attention to investment risks.
(III) the company solemnly reminds investors that China Securities News, Shanghai Securities News, securities daily and securities times are the newspapers and periodicals designated by the company for information disclosure, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks.
5、 Online announcement attachment
Reply to inquiry letter on matters related to abnormal fluctuation of Shenzhen Yhlo Biotech Co.Ltd(688575) stock trading.
It is hereby announced.
Shenzhen Yhlo Biotech Co.Ltd(688575) board of directors March 12, 2022
